Heart failure startup emerges with $42 million in financing for its intelligent fluid management system
Amount Raised
$42 Million
Round Type
Series A
MilfordHealthcareHealth CareInvestors
Description
Reprieve Cardiovascular Inc. announced a $42 million Series A financing round to advance clinical trials for its automated diuretic and fluid management treatment for acute decompensated heart failure (ADHF). The funding will advance the company’s clinical programs, including the ongoing FASTR trial and its upcoming pivotal trial, and reinforce the belief in the need for a new technology to improve the lives of patients suffering from ADHF around the world.
Quick answer
Reprieve Cardiovascular raised $42 Million in a Series A round, dated February 21, 2024. Investors: Arboretum Ventures, Genesis Capital, Deerfield Management, Sante Ventures and Lightstone Ventures. Reprieve Cardiovascular is based in Milford, Massachusetts, United States.
- How much did Reprieve Cardiovascular raise?
- Reprieve Cardiovascular raised $42 Million in a Series A round on February 21, 2024.
- Who invested in Reprieve Cardiovascular?
- Arboretum Ventures, Genesis Capital, Deerfield Management, Sante Ventures and Lightstone Ventures are named as investors in this round.
- What does Reprieve Cardiovascular do?
- Reprieve Cardiovascular Inc. is a startup focusing on developing an intelligent fluid management system for acute decompensated heart failure.
- Where is Reprieve Cardiovascular based and how big is it?
- Reprieve Cardiovascular is based in Milford, Massachusetts, United States. Fundz records about 25 employees.
- Who are the decision-makers at Reprieve Cardiovascular?
- Fundz holds 1 contact at Reprieve Cardiovascular, including the Executive Officer. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Healthcare and Health Care around the same time
Companies in the same sectors as Reprieve Cardiovascular that raised within 45 days of this round, from Fundz verified event records.
- Enlaza Therapeutics raised $84M on April 5, 2024.
- Miach Orthopaedics raised $20M (Series B) on April 2, 2024.
- Melt Pharmaceuticals raised $24M (Series B) on April 2, 2024.
- Vaccinex raised $1.8M (Seed) on March 29, 2024.
- ByHeart raised $95M on March 28, 2024.
- Miach Orthopaedics raised $20M on March 28, 2024.
Who to call at Reprieve Cardiovascular, and when
A new round usually means Reprieve Cardiovascular is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Reprieve Cardiovascular raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Reprieve Cardiovascular, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Reprieve Cardiovascular. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Reprieve Cardiovascular raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansReprieve Cardiovascular raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.